|
P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol |
|
|
|
Title: |
P-216: Daratumumab, Carfilzomib, Lenalidomide, & Dexamethasone for relapsed/refractory Myeloma with salvage autologous hematopoietic cell transplant: interim analysis of the multicenter 2nd chance protocol |
Author: |
Shah, Gunjan Bal, Susan Rodriguez, Cesar Chhabra, Saurabh Bayer, Ruthee Costa, Luciano Lambird, Jonathan Ferrer, Christine Parascondola, Allison Marcello, Leeann Shulman, Leah Obadi, Obadi Acosta, Jennifer Hassoun, Hani Hultcrantz, Malin Korde, Neha Mailankody, Sham Tan, Carlyn Shah, Urvi Lesokhin, Alexander Lahoud, Oscar Scordo, Michael Chung, David Landau, Heather Giralt, Sergio |
Appeared in: |
Clinical lymphoma myeloma and leukemia |
Paging: |
Volume 21 () nr. S2 pages S158-S159 |
Year: |
2021 |
Contents: |
|
Publisher: |
Elsevier Inc. |
Source file: |
Elektronische Wetenschappelijke Tijdschriften |
|
|
|
|